HYTN Innovations Acquires Prism Labs To Boost Psychedelic Drug Manufacturing Capabilities
HYTN Innovations Inc (CSE:HYTN), a leader in the development and manufacture of psychoactive and psychotropic compounds, including cannabis and psilocybin, has completed the acquisition of Prism Scientific Labs Inc, as announced in their July 19 press release. This strategic move is intended to strengthen HYTN’s capabilities in the manufacture of psychedelic compounds.
Strategic Acquisition
The acquisition aims to enhance HYTN’s manufacturing processes, and specifically to increasing the yield of tryptamine in psychedelic mushrooms, and grants HYTN exclusive access to Prism’s intellectual property, including a significant license from Lux Sit Systems Inc. The specialized equipment and technologies associated with this license are designed to increase both the yield and potency of psilocybin-containing mushrooms, essential to the manufacture of psychedelic drugs.
The license agreement, secured by Prism in June 2024, is …